Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

s and increasing their risk of developing treatment-related acute myeloid leukemia.

To understand if ibrutinib may be effective for elderly CLL patients and to identify which patients might benefit most from the drug, researchers enrolled 116 CLL patient participants in several treatment cohorts: patients who were never treated (the treatment-nave group), those who had received two or more prior therapies (the relapsed/refractory group), those who had relapsed within two years of treatment (the high-risk group), and those over age 65. Two oral dosing regimens (420 mg or 840 mg daily) of ibrutinib were used. The primary goal of the study was to determine the safety of the low and high doses; secondary objectives included efficacy, measures of the intensity of the drug's effect in the body, and the long-term safety of administering this therapy continuously until relapse.

The study found that response to therapy was high across the cohorts, with largely manageable toxicities. Previously untreated elderly patients responded best to the agent, with 71 percent experiencing a complete or partial response at either treatment dose. The same response was observed in 67 percent of the relapsed patients and 50 percent of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

The treatment regimen was generally well-tolerated, as only non-severe side effects were observed, including diarrhea, fatigue, chest infection, rash, nausea, joint pain, and infrequent and transient low blood counts. Investigators found no evidence of cumulative toxicity or long-term safety concerns with a median follow-up of 16 months for treated patients. These results demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL.

"As we learn more about how to target specific essential survival signa
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... VA (PRWEB) July 29, 2014 The ... members of the Deadliest Cancer Coalition, led advocacy efforts ... officials in the newly established Congressional Caucus on the Deadliest ... efforts, the caucus now features the following 20 members: , ... Eshoo (CA-18) – May 2, 2014, Rep. Zoe Lofgren (CA-19) ...
(Date:7/29/2014)... electroacupuncture (EA) a form of acupuncture where ... of acupuncture needles produces significant improvements in ... eight weeks for early stage breast cancer patients ... aromatase inhibitors (AIs) to treat breast cancer. The ... intervention led by researchers at the Perelman School ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... Daily Gossip indicates in its Natural Cure for ... any sufferer who is looking for an all-natural holistic cure ... new program, Sarah Summer, says that her method is 100 ... too. Actually, this is the reason why she was so ... The Natural Cure for Yeast Infection review indicates ...
(Date:7/29/2014)... July 29, 2014 For numerous women from ... relationship work can turn out being quite hard. Well, the ... he discovered the method that can help all these women. ... make a guy show love and attention every day. ... method was actually created by Alex Carter who published a ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 3Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:"Make Him Desire You" Review Reveals Unique Formula to Make Men Feel a Special Kind of Love 2
... is not an option, survey finds, , TUESDAY, July 21 ... try to buy an individual health insurance policy on their ... are just too expensive, according to a new study. , ... supports independent research on health policy reform, found that roughly ...
... ... better serve residents, families , ... Wausau, Wisc. (Vocus) July 21, 2009 -- My InnerView, the leading provider ... today announced the creation of the My SeniorCare Edvantage Program, an online health management ...
... LAWRENCE, Mass. , July 21 NxStage Medical, ... innovative dialysis products, today announced that its Medisystems subsidiary has ... Fenwal, Inc. of Lake Zurich, Ill. Medisystems provides needle ... focused on improving blood collection, separation, safety and availability for ...
... child welfare practices from across the country offer hope for America,s most ... SEATTLE, July 21 All across America, child welfare systems are ... improving the lives of children in foster care as well as children ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070116/CASEYFAMILYLOGO ) , ...
... , , , , ... food company, today announced the launch of TLC(R) Dark Mocha Almond Chewy ... TLC(R) Chewy Granola Bar family. This new granola bar combines crunchy ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090331/LA91619LOGO ) ...
... /PRNewswire/ - (Ocean Nutrition Canada) - These days, ... purchase dollars, buying products that are local, recycled, ... consumerism is literally changing the world: If given ... products from certified sustainable sources, research from the ...
Cached Medicine News:Health News:Millions in U.S. Can't Afford Health Insurance 2Health News:My InnerView and UW-Eau Claire Announce New Online Health Management Certificate Program for Senior Care Professionals 2Health News:My InnerView and UW-Eau Claire Announce New Online Health Management Certificate Program for Senior Care Professionals 3Health News:NxStage(R) Announces Extension of Medisystems Needle Supply and Distribution Agreement 2Health News:New Report Sets a Course for Improving Foster Care Systems 2Health News:New Report Sets a Course for Improving Foster Care Systems 3Health News:Kashi Company Introduces TLC(R) Dark Mocha Almond Chewy Bar 2Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 2Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 3Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 4Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 5Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 6
(Date:7/29/2014)... SAN DIEGO , July 29, 2014 Pfenex ... its previously announced initial public offering of 8,333,333 shares of ... $6.00 per share. All of the common stock was offered ... 30-day option to purchase up to 1,250,000 additional shares of ... of common stock are traded on the NYSE MKT under ...
(Date:7/29/2014)... July 29, 2014  Covance Inc. (NYSE: ... ended June 30, 2014.  Net revenue was $639 million, ... On a GAAP basis, the company reported earnings of ... company reported pro forma earnings per diluted share of ... Pro forma results exclude asset impairment charges totaling $52.6 ...
(Date:7/29/2014)... , July, 29  2014 ISPE—the International ... hired John Bournas as President and ... plans to leave the Society last fall.  Mr. ... competencies in the healthcare association industry as well ... Society a clear vision for the expansion of ...
Breaking Medicine Technology:Pfenex Announces Closing of Initial Public Offering 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3
Safe. Reliable. Baby-friendly. ,The Hugs infant protection system helps to protect your infants and children from the threat of abduction....
The AeroScout Exciter extends the AeroScout system to provide robust and sophisticated RFID detection capabilities....
... VerdaSee Intelli-Storeroom™ was developed to create ... Room entrances and exits are converted to ... with RFID readers and antennas by VerdaSee's ... are affixed to assets that are to ...
... Aspects provides hospitals with a ... track all their supplies, drugs, ... systems remove all manual compliance ... people accurately. iRIS, or Intelligent ...
Medicine Products: